<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="105702">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01658462</url>
  </required_header>
  <id_info>
    <org_study_id>VAROCE - 1206</org_study_id>
    <nct_id>NCT01658462</nct_id>
  </id_info>
  <brief_title>Phase II Study of Docetaxel +/- Nintedanib in Breast Cancer</brief_title>
  <acronym>VAROCE</acronym>
  <official_title>A Phase II Randomized Study of Docetaxel With or Without NINTEDANIB (BIBF-1120) in Patient Receiving a Second-line of Chemotherapy for HER Negative Metastatic or Locally Recurrent Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <authority>France: Committee for the Protection of Personnes</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Second-line chemotherapy for metastatic or locally recurrent breast cancer
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>increase in the progression free survival (PFS) in patients receiving Docetaxel + Nintedanib treatment (Arm A)  compared to Docetaxel alone (Arm B)</measure>
    <time_frame>baseline, every 3 weeks, up to 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>6-months progression free disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>response rate</measure>
    <time_frame>baseline, every 3 weeks, up to 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>time from the date of randomization to the date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>baseline, every 3 weeks, up to 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>EORTC QLQ C30 (Additional module BR23)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biological markers levels in tumors and endothelial cells</measure>
    <time_frame>baseline, every 9 weeks, up to 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>biological analysis of cells RT-qPCR analysis, including endothelial cells using a specific reference gene</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biological markers in patient serum</measure>
    <time_frame>baseline, every 9 weeks, up to 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>biological analysis in patient's serum Dosage of VEGF-A, -C, FGF-1, -2, PDGF-AA, -AB, -BB in patient's serum</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Locally Recurrent or Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel + Nintedanib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel + increase of the dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>75 mg/m2 IV Day 1 / 3 weeks Arm B : dose can be increased to 100 mg/m2 secondarily on cycle 2</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nintedanib</intervention_name>
    <description>200 mg x 2 per os daily No Nintedanib on days when docetaxel is administered</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years old

          -  Histologically or cytologically confirmed adenocarcinoma of the breast

          -  Locally recurrent or metastatic disease

          -  HER 2 negative status

          -  Prior first line chemotherapy not containing Docetaxel

          -  Relapsing after a first line chemotherapy for locally recurrent or metastatic disease

          -  Measurable or evaluable disease according to RECIST criteria

          -  Prior chemotherapy as follows :

               -  Docetaxel in the neoadjuvant or adjuvant setting is allowed provided that
                  relapse has been observed more than 12 months after the end of docetaxel
                  treatment

               -  Bevacizumab in 1st line is allowed with a wash-out of 3 months

          -  ECOG performance status 0-1

          -  Adequate bone marrow, hepatic and renal functions as evidence by the following:

               -  Hemoglobin ≥ 10 G/100 mL

               -  Neutrophils count  ≥ 1500 /mm3

               -  Platelets ≥ 100 000 /mm3

               -  Total bilirubin ≤ ULN (ULN:Upper Limit of Normal)

               -  SGOT/SGPT ≤ 1.5 x ULN (≤ 2.5 x ULN in case of hepatic metastasis)

               -  Creatinin clearance ≥ 45 ml/min or creatinin ≤ 1.5 x ULN

               -  Proteinuria &lt; CTCAE grade 2

          -  Coagulation parameters: International normalised ratio (INR) ≤ 2, prothrombin time
             (PT) and partial thromboplastin time (PTT) ≤ 50% of deviation  of institutional ULN

          -  Effective contraception for patients (male and female) of reproductive potential
             during their entire participation in the study and during 3 months after the last
             administration of Nintedanib or Docetaxel

          -  Negative pregnancy test (serum beta-HCG) within 1 week prior to start of study
             treatment in females of reproductive potential

          -  Patient covered by government health insurance

          -  Signed and dated written informed consent prior to  admission to the study in
             accordance with ICH-GCP guidelines and to the local legislation

        Exclusion Criteria:

          -  Symptomatic brain metastasis

          -  Concomitant hormone therapy for metastatic breast cancer

          -  Patients with dysphagia, or inability to swallow the tablets

          -  Other serious illness or medical conditions: Cardiac disease

          -  Unstable diabetes

          -  Uncontrolled hypercalcemia

          -  Clinically significant active infections

          -  Pregnancy or breast feeding woman

          -  Unable for medical follow-up (geographic, social or mental reasons)

          -  Prior treatment with Nintedanib or any other VEGFR inhibitor or stratify if trial
             aims to establish anti-angiogenic retreatment

          -  Known hypersensitivity to the trial drugs , to their excipients or to contrast media

          -  Contra indication to the use of the backbone treatment and to the comparator

          -  Active brain metastases (e.g. stable for &lt;4 weeks, no adequate previous treatment
             with radiotherapy, symptomatic, requiring treatment with anti-convulsants;
             dexamethasone therapy will be allowed if administered as stable dose for at least one
             month before randomisation)

          -  Leptomeningeal disease

          -  Radiographic evidence of cavitary or necrotic tumors

          -  Centrally located tumors with radiographic evidence (CT or MRI) of local invasion of
             major blood vessels

          -  History of clinically significant haemorrhagic or thromboembolic event in the past 6
             months

          -  Known inherited predisposition to bleeding or thrombosis

          -  Significant cardiovascular diseases ( i.e. uncontrolled hypertension, unstable
             angina, history of infarction within the past 12 months prior to  start of study
             treatment, congestive heart failure &gt; NYHA II, serious cardiac arrhythmia,
             pericardial effusion)

          -  Other malignancies within the past 5 years other than basal cell skin cancer or
             carcinoma in situ of the cervix

          -  Active serious infections in particular if requiring systemic antibiotic or
             antimicrobial therapy

          -  Active or chronic hepatitis C and/or B infection

          -  Active alcohol or drug abuse

          -  Significant weight loss (&gt; 10% of BW) within past 6 months prior to inclusion into
             the trial
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacques BONNETERRE, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Oscar Lambret Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacques BONNETERRE, MD PhD</last_name>
    <phone>+33 (0)3.20.29.55.50</phone>
    <email>j-bonneterre@o-lambret.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>South Hospital</name>
      <address>
        <city>Amiens</city>
        <zip>80 054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine PIPROT, MD</last_name>
      <phone>+33 (0)3.22.45.56.99</phone>
      <email>pipro.christine@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Christine PIPROT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno CHAUFFERT, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leonard de Vinci Center</name>
      <address>
        <city>Dechy</city>
        <zip>59 187</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire GIRAULT, MD</last_name>
      <phone>+33 (0)3.27.08.60.63</phone>
      <email>cgiraud@clinique-psv.fr</email>
    </contact>
    <investigator>
      <last_name>Claire GIRAUD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Virginie POTTIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas REZVOY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oscar Lambret Center</name>
      <address>
        <city>Lille</city>
        <zip>59 020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques BONNETERRE, MD PhD</last_name>
      <phone>+33 (0)3.20.29.55.50</phone>
      <email>j-bonneterre@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>Jacques BONNETERRE, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Audrey MAILLIEZ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Véronique SERVENT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurence VANLEMMENS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Cancerology Institut</name>
      <address>
        <city>St HERBLAIN</city>
        <zip>44 805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hervé CURE, MDPhD</last_name>
      <phone>+33 (0)3.26.50.44.87</phone>
      <email>herve.cure@reims.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Hervé CURE, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christelle JOUANNAUD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>J-Christophe EYMARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aude-Marie SAVOYE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gabriel YAZBEK, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brigitte COSTA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alexis Vautrin Center</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54 500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria RIOS, MD</last_name>
      <phone>+33 (0)3.83.59.85.66</phone>
      <email>m.rios@nancy.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Maria ROSS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mathilde DEBLOCK, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 5, 2013</lastchanged_date>
  <firstreceived_date>July 31, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>Nintedanib</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
